Industry news

• Collaboration to support quality production of biologics

  01 March 2023 Catherine Eckford / European Pharmaceutical Review

  US Pharmacopeia (USP) and American Type Culture Collection (ATCC) will collaborate to better support the biologics sector in R&D, process development and release of high-quality biologics.

• First successful CAR-T treatment for muscle inflammation

  01 March 2023 Catherine Eckford / European Pharmaceutical Review

  Researchers in Germany have helped a patient to overcome anti-synthetase syndrome muscle inflammation using CAR-T cells.

• Bioavailability enhancement services market to exhibit 11 percent CAGR

  28 February 2023 Catherine Eckford / European Pharmaceutical Review

  Between 2022 and 2035, the bioavailability enhancement services market will see an 11 percent compound annual growth rate, a report has predicted.

• A resident of Skolkovo has received a license for an early cancer detection laboratory

  28 February 2023 GxPnews

  At the first stage of the project, which starts in 2023, Oncodiag will perform tests for the level of CA-62, an innovative marker developed at Skolkovo by Javis Diagnostics. Studies have shown that this marker most effectively (with up to 95% accuracy) detects epithelial tumors in the early stages of cancer (up to 90% of all cancer cases), including lung, ovarian, prostate, breast, and colorectal cancer.

• A vaccine against allergy to birch pollen has been developed by FMBA

  27 February 2023 GxPnews

  The birch pollen allergy vaccine developed by the State Research Center Institute of Immunology of the Federal Medical and Biological Agency (FMBA) of Russia together with the Vienna Medical University protects from allergy after three to five injections, unlike extract-based vaccines available in the market, which have to be administered up to 30 times. This was announced by Igor Shilovsky, Deputy Director for Science and Innovation of the Institute.

• Pharma spending on linear TV ads falls for first time in years, accelerating transition to digital

  27 February 2023 Nick Paul Taylor / FierceBiotech

  Was last year a tipping point in the transition to digital pharma advertising? A fresh slice of data from Standard Media Index suggests that might be the case, revealing spending on linear TV fell for the first time in years and that digital’s share of the media mix passed 50%.

• Russia has launched IVF drugs production

  22 February 2023 GxPnews

  Aleksandr Petrov, Chairman of the Board of Directors of OOO “Zavod Medsintez,” has stated the risk of disappearance of drugs for the treatment of female infertility from the Russian market, TASS reports. At the moment, most drugs for women’s reproductive health in Russia are imported, and if such supplies stop, IVF programs will become impossible.

• Drug resistance in non-small cell lung cancer could be curbed with CD70-targeted therapies

  22 February 2023 Helen Floersh / FierceBiotech

  Many patients with EGFR-mutated non-small cell lung cancer, or NSCLC, face a frustrating prognosis. While initial treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs) works well, “persister” cells that are left behind will almost certainly cause the cancer to return. The disease becomes much harder to fight when it comes back, as the new tumors are highly resistant not only to TKIs but other drugs as well.

• The FMBA will open four more new plasma centers in the regions

  21 February 2023 GxPnews

  The Agency will open new plasma centers in Nizhny Novgorod, Chuvashia, the Republic of Mari El, and the Perm Krai in the next two years. This will help to increase the volume of blood plasma harvesting, including for the production of domestic drugs and solving the issue of import dependence.

• Fusion to acquire radiologand therapy for prostate cancer

  21 February 2023 Catherine Eckford / European Pharmaceutical Review

  An investigational new drug application for an ongoing Phase II trial of an alpha-emitting radiopharmaceutical will be acquired by Fusion Pharmaceuticals.